| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 07/02/2002 | CA2054699C Growth of vascular endothelial cell growth factor and dna encoding same |
| 07/02/2002 | CA2047283C Pyrazolopyridine compound and processes for preparation thereof |
| 06/27/2002 | WO2002050290A1 A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell |
| 06/27/2002 | WO2002050289A1 Methods for the production of multimeric proteins, and related compositions |
| 06/27/2002 | WO2002050286A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 06/27/2002 | WO2002050284A2 Oxidoreductases |
| 06/27/2002 | WO2002050279A2 Nucleic acid-associated proteins |
| 06/27/2002 | WO2002050270A1 Novel tissue-specific secretory polypeptide and dna thereof |
| 06/27/2002 | WO2002050255A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof |
| 06/27/2002 | WO2002050125A2 Glycosaminoglycans derived from k5 polysaccharide having high antithrombin activity and process for their preparation |
| 06/27/2002 | WO2002050105A1 Novel compounds |
| 06/27/2002 | WO2002050101A1 Retinoblastoma-binding protein |
| 06/27/2002 | WO2002050096A1 Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 06/27/2002 | WO2002050090A1 Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| 06/27/2002 | WO2002050085A1 A new process for preparing fused 1,2,4-thiadiazine derivatives |
| 06/27/2002 | WO2002050073A1 Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| 06/27/2002 | WO2002050071A1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 06/27/2002 | WO2002050070A2 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists |
| 06/27/2002 | WO2002050068A1 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| 06/27/2002 | WO2002050067A2 Pharmaceutical heterocyclic compounds |
| 06/27/2002 | WO2002050066A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050065A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050060A1 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| 06/27/2002 | WO2002050056A1 Benzylamine derivatives and their use as thrombin inhibitors |
| 06/27/2002 | WO2002050051A1 Chemical compounds |
| 06/27/2002 | WO2002050047A1 Substitued oxazoles and thiazoles as hppar alpha agonists |
| 06/27/2002 | WO2002050044A1 Novel 2,3-benzodiazepine derivatives and pharmaceutical compositions containing the same as the active ingredient |
| 06/27/2002 | WO2002050041A1 Dihydroindole and tetrahydroquinoline derivatives |
| 06/27/2002 | WO2002050039A1 Urea and urethane derivatives as integrin inhibitors |
| 06/27/2002 | WO2002050036A1 Crystalline forms of cerivastatin sodium |
| 06/27/2002 | WO2002050033A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 06/27/2002 | WO2002050032A1 Naphthalene derivatives which bind to the ep4 receptor |
| 06/27/2002 | WO2002050031A1 Indole derivatives |
| 06/27/2002 | WO2002050028A2 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | WO2002050027A1 Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| 06/27/2002 | WO2002050021A1 Nitric oxide synthase inhibitor phosphate salt |
| 06/27/2002 | WO2002050019A2 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | WO2002049993A2 High affinity small molecule c5a receptor modulators |
| 06/27/2002 | WO2002049714A2 Electrically responsive promoter system |
| 06/27/2002 | WO2002049669A2 Electrically responsive promoter system |
| 06/27/2002 | WO2002049651A1 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049650A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049649A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 06/27/2002 | WO2002049648A1 Heteroaryl urea neuropeptide y y5 receptor antagonists |
| 06/27/2002 | WO2002049646A1 Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 06/27/2002 | WO2002049645A1 Therapeutic combination of amlodipine and benazepril |
| 06/27/2002 | WO2002049642A2 Use of 5-hydroxy and 5-acyloxy-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic acids and their esters as agents useful for healing skin lesions and stimulants of angiogenesis |
| 06/27/2002 | WO2002049635A2 Use of 5-aminolevulinic acid for the prophylaxis of restenosis |
| 06/27/2002 | WO2002049626A2 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity |
| 06/27/2002 | WO2002030353A3 NF-λB INHIBITORS |
| 06/27/2002 | WO2002022602A3 Triazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002022592A3 Substituted urea neuropeptide y y5 receptor antagonists |
| 06/27/2002 | WO2002020822A3 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 06/27/2002 | WO2002020566A3 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3? |
| 06/27/2002 | WO2002020501A3 Polyarylcarboxamides useful as lipid lowering agents |
| 06/27/2002 | WO2002002182A3 Shelf storage stable iontophoresis reservoir-electrode and iontophoretic system |
| 06/27/2002 | WO2001097788A3 Method of administering bisphosphonates |
| 06/27/2002 | WO2001096298A3 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase |
| 06/27/2002 | WO2001092267A3 Dihydropyridine compounds for the inhibition of calcium-influx |
| 06/27/2002 | WO2001083746A3 Regulatory nucleic acid sequences of the abc1 gene |
| 06/27/2002 | WO2001082858A3 Novel compounds for the treatment of inflammatory and cardiovascular diseases |
| 06/27/2002 | WO2001077375A3 Diagnosis of diseases associated with gene regulation |
| 06/27/2002 | WO2001077095A3 Derivatives of alpha-mercaptoacetamide |
| 06/27/2002 | WO2001076584A3 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 06/27/2002 | WO2001073025A3 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 06/27/2002 | WO2001070978A3 Polypeptides and nucleic acids encoding same |
| 06/27/2002 | WO2001053257A3 Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them |
| 06/27/2002 | WO2000056350A9 Methods of use of beta 1-integrin inhibitors |
| 06/27/2002 | US20020082620 Bioactive materials for aneurysm repair |
| 06/27/2002 | US20020082435 For use in cancer therapy |
| 06/27/2002 | US20020082304 Containing combination inhibitor, combination inhibitor which acts both to interfere with the isolation of sympathomimetic amine from the composition and to interfere with conversion of sympathomimetic amine to another drug |
| 06/27/2002 | US20020082300 1-((5-(2-(5-tert-Butyl-2-methoxybenzamido)ethyl)-2-methoxyphen yl)- sulfonyl)-3-methylthiourea and propanolol for example |
| 06/27/2002 | US20020082292 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma |
| 06/27/2002 | US20020082278 Use to treat allergy, nasal congestion, inflammatory and central nervous system-related diseases |
| 06/27/2002 | US20020082274 Preparation of sodium-hydrogen exchanger type-1 inhibitors |
| 06/27/2002 | US20020082272 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 06/27/2002 | US20020082269 Purine-2,6-dione based compounds as receptor binding assay probes and pharmaceuticals; high potency and affinity with water solubility |
| 06/27/2002 | US20020082266 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore |
| 06/27/2002 | US20020082261 Prophylactic or therapeutic agents for diseases haivng vascular dysfunction associated with insulin resistance |
| 06/27/2002 | US20020082257 Elevates ATP binding cassette transporter 1 expression thereby increasing efflux of cholesterol from cells by active transfer into high density lipoproteins |
| 06/27/2002 | US20020082256 Compounds useful as anti-inflammatory agents |
| 06/27/2002 | US20020082255 Substituted ureas |
| 06/27/2002 | US20020082250 Beta lactams as antiproliferative agents |
| 06/27/2002 | US20020082246 Prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading enzymes is involved; these include degenerative joint disorders such as osteoarthroses and disorders of connective tissue |
| 06/27/2002 | US20020082242 Compositions and methods of double-targeting virus infections and cancer cells |
| 06/27/2002 | US20020082241 Adenosine as antithrombotic |
| 06/27/2002 | US20020082235 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof |
| 06/27/2002 | US20020082221 Nitric-oxide releasing lipid molecules selected from phosphoglycerides, lipids having a sphingosine base as a backbone, a monoglyceride, a diglyceride, a glycosylacylglycerol and a sterol containing S-N=O, N-N=O or |
| 06/27/2002 | US20020082219 Dendroaspis(green mamba snake) natriuretic peptide has at least one activity selected from the group consisting of vasodilation, antriuresis, diuresis and renin-suppressing activity |
| 06/27/2002 | US20020082215 Administering to nasal cavity of mammal a pharmaceutical composition comprising therapeutically effective amount of insulin-like growth factor-I or biologically active variant thereof |
| 06/27/2002 | US20020082205 Human FGF-23 gene and gene expression products |
| 06/27/2002 | US20020082032 Access parameter adaptation and packet data resource management using detailed mobile status information |
| 06/27/2002 | US20020081695 Nucleotide sequences coding polypeptide for use in the treatment of blood disorders, gout, kidney stones, Lesch-Nyhan syndrome, renal failure and uricaciduria |
| 06/27/2002 | US20020081659 Nucleic acids, proteins and antibodies |
| 06/27/2002 | US20020081633 Methods for using 22045, a human cyclic nucleotide phosphodiesterase |
| 06/27/2002 | US20020081290 Protein kinase homologs |
| 06/27/2002 | US20020081288 A polypeptide selected from the group consisting of a SOD-4 polypeptide (superoxide dimutase) having a preferred deduced amino acid sequence and fragments, analogs and derivatives encoded by a specific polynucleotide |
| 06/27/2002 | US20020081286 NRG-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 06/27/2002 | DE10137038A1 N-3,7 Substituted 1-Methylxanthine Derivates Displaying Inhibitory Activites on Type Five Phosphodiesterase N-Substituted 3,7-methylxanthine derivative Displaying 1 Inhibitory Activites on phosphodiesterase Type Five |
| 06/27/2002 | DE10063076A1 Verwendung von 5-Aminolävulinsäure zur Restenose-Prophylaxe Use of 5-aminolevulinic acid for restenosis prophylaxis |